Soleus Capital Management L.P. Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Soleus Capital Management L.P. grew its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 97.3% during the fourth quarter, HoldingsChannel reports. The fund owned 2,102,833 shares of the company’s stock after acquiring an additional 1,036,999 shares during the quarter. Nurix Therapeutics comprises about 2.5% of Soleus Capital Management L.P.’s holdings, making the stock its 12th largest position. Soleus Capital Management L.P.’s holdings in Nurix Therapeutics were worth $39,617,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in NRIX. US Bancorp DE boosted its position in Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after purchasing an additional 842 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Nurix Therapeutics during the fourth quarter valued at about $87,000. Summit Investment Advisors Inc. boosted its holdings in shares of Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock valued at $138,000 after buying an additional 877 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Nurix Therapeutics in the 4th quarter worth approximately $164,000. Finally, Nomura Holdings Inc. bought a new position in shares of Nurix Therapeutics during the 4th quarter worth approximately $198,000.

Nurix Therapeutics Trading Up 1.1%

Shares of NASDAQ NRIX opened at $9.56 on Monday. The company has a 50 day simple moving average of $11.07 and a two-hundred day simple moving average of $16.80. The stock has a market cap of $728.82 million, a price-to-earnings ratio of -3.31 and a beta of 2.23. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The company had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. During the same period in the previous year, the firm posted ($0.76) earnings per share. Analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the transaction, the insider now directly owns 61,516 shares of the company’s stock, valued at $707,434. The trade was a 5.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Houte Hans Van sold 6,198 shares of the business’s stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $382,092.92. This represents a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,838 shares of company stock worth $221,500. Insiders own 7.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Stifel Nicolaus decreased their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th. Stephens reaffirmed an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Wells Fargo & Company lowered their price objective on Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, April 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $27.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Finally, Leerink Partnrs upgraded Nurix Therapeutics to a “hold” rating in a research note on Monday, March 17th. Three analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $30.44.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.